China Resources Sanjiu Medical & Pharmaceutical Co Ltd (000999) Income Statement
An income statement shows a company's revenue, expenses, and profit over a reporting period.
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in the People's Republic of China and internationally.
Total Revenue Chart for China Resources Sanjiu Medical & Pharmaceutical Co Ltd
China Resources Sanjiu Medical & Pharmaceutical Co Ltd (000999) revenue for FY2025 was CNY 31.6B, a 14.4% change from FY2024. China Resources Sanjiu Medical & Pharmaceutical Co Ltd's revenue grew from CNY 1.1B in 1997 to CNY 31.6B in 2025 (2747.5% over 28 years). Earnings per share grew from CNY 0.16 in 2000 to CNY 1.47 in 2022 (826.5%). Revenue compound annual growth rate: 5-year CAGR of 18.3%, 10-year CAGR of 14.9%, 20-year CAGR of 12.6%.
Total Revenue (CNY)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- ¥40.59B
- Implied Share Price
- ¥24.39
- Enterprise Value
- ¥38.28B
- Revenue (TTM)
- ¥31.81B
- EBITDA
- ¥5.32B
- Profit Margin
- 10.30%
- Trailing P/E
- 12.38
- Forward P/E
- 16.47
- Price/Book (MRQ)
- 1.80
- Price/Sales (TTM)
- 1.28
- EV/EBITDA
- 5.97
- EV/Revenue
- 1.20
- Dividend Yield
- 4.08%
- Book Value
- ¥13.72
- Free Cash Flow (FY2025)
- ¥4.24B
- Free Cash Flow Yield
- 10.45%
Snapshot as of 28th August 2026 — not point-in-time controlled, may lag the live market by a few days.